Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413771 | 0.82 | ERN1 (0.53) | ERN1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL31551028 | 0.82 | ERN1 (0.53) | ERN1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL1748175 | 0.81 | ERN1 (0.66) | ERN1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL14292141 | 0.81 | ERN1 (0.51) | ERN1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL2300015 | 0.80 | ERN1 (0.46) | ERN1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL7522554 | 0.80 | ERN1 (0.52) | ERN1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL2389960 | 0.79 | ERN1 (0.55) | ERN1ALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL3664240 | 0.79 | ERN1 (0.50) | ERN1ALDH1A1HPGDTDP1MEN1 | |
| SCHEMBL12504651 | 0.79 | SCN4A (0.44) | ALDH1A1HPGDTDP1MEN1KMT2A | |
| SCHEMBL10023122 | 0.78 | ERN1 (0.47) | ERN1ALDH1A1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-0117035-B1 | ALDOSE REDUCTASE INHIBITING 5-(2-ALKOXYPHENYL)THIAZOLIDINEDIONES | PFIZER INC. (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0112620-B1 | 5-(SUBSTITUTED PHENYL) HYDANTOINS | PFIZER INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4617312-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0117035-A2 | Aldose reductase inhibiting 5-(2-alkoxyphenyl)thiazolidinediones | PFIZER INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0112620-A1 | 5-(Substituted phenyl) hydantoins | PFIZER INC. (US) | 1984-07-04 | — | — | EP | disclosed |
| US-4457939-A | DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1984-07-03 | — | — | US | disclosed |
| US-4448971-A | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4407811-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4399296-A | TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4367234-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | ERN1 610/4885ALDH1A1 455/4885HPGD 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.